Brief: Passage Bio Announces 1-For-20 Reverse Stock Split
Brief: Passage Bio Reports Updated Interim Data From Uplift-D Study
Passage Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Passage Bio Q1 Income From Operations USD -16.459 Million
Passage Bio Inc expected to post a loss of 23 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accolade, Crowdstrike, Marriott International
Passage Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Passage Bio Reports Fourth Quarter and Full Year 2024 Results
Passage Bio Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Passage Bio Inc On Jan 8, Board Approved, And Management Began Implementing, Restructuring Plan
U.S. STOCKS ON THE MOVE-Prologis, Malibu Boats, Silo Pharma
Passage Bio gains as Wedbush assumes coverage with 'outperform' rating
Brief: Vestal Point Capital Reports 9.9% Passive Stake In Passage Bio As Of Sept 30 - SEC Filing
Passage Bio Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Passage Bio Reports Third Quarter 2024 Financial Results And Provides Recent Business Highlights
Passage Bio Inc expected to post a loss of 23 cents a share - Earnings Preview
Passage Bio Inc reports results for the quarter ended in June - Earnings Summary
Passage Bio Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Passage Bio Inc On July 31, Entered Series Of Sublicense Agreements With Gemma